Publication | Open Access

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

MedicineCancer ManagementGynecologyFallopian Tube CancerImmune Checkpoint InhibitorPharmacotherapyPrimary PeritonealCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer